Organs-on-chip (OC) have gained high interest as animal-free toxicity testing method due to their higher resemblance to human tissues and longer culture viability than conventional in vitro methods. The current paper discusses where and how OCs may take a role in the transition to a more predictive, animal-free safety assessment for regulatory purposes. From a preliminary analysis of a repeated dose toxicity database, ten organs of priority for OC development for regulatory use have been identified. For a number of these organs (lung, skin, liver, kidney, heart, and intestine), OCs are already at rather advanced stages of development, such that involvement of regulators becomes of value in the optimization towards fitness-for-purpose of these methods. For organs such as testis, spleen, brain, and stomach, OCs are much more premature, if existing at all. Therefore, developmental work on OCs for these latter organs is expected to stay in the academic arena for the coming time. A number of technical recommendations and some challenges in reaching final implementation are discussed. We recommend the development of OCs to go together with the development of Adverse Outcome Pathways and combining them with other methods into integrated testing strategies. Overall, opportunities exist, but there is still much that needs to be done. In our view, regular interactions in multi-stakeholder workshops on application of animal-free innovations such as OCs will be beneficial.
Introduction
Traditionally, much of the data for regulatory safety assessment of chemical substances and pharmaceuticals comes from experimental animal studies. In fact, in Europe approximately 9% of the total number of test animals is used for safety assessment (EC, 2013) . However, over the last decades it has become increasingly apparent that animal studies may have limited predictive value for various toxic effects in humans (e.g. (Adler et al., 2011; Arrowsmith and Miller, 2013) ). To overcome this, regulatory safety assessments should make much more use of the increased knowledge on the mechanisms underlying toxic effects that was gained since the era when today's regulatory toxicity studies were devised. Besides this scientific argument, ethical and economic arguments further challenge the use of laboratory animals. Government, industry and academia's collaborative investment in replacement, refinement and reduction of animal experiments (3Rs) have already led to a toolbox with various animal-free toxicity testing methods for use in regulatory safety assessment, but a complete replacement of animal tests is not yet possible. Especially in case of the more complex, systemic endpoints (e.g. carcinogenicity and reproductive toxicity), adequate animal-free methods are not yet available. Similarly, sufficiently predictive animal-free models to obtain information on toxicokinetics (absorption, metabolism, and excretion), which is indispensable to calculate safe exposure limits for humans from in vitro assays, are still lacking. In short, from a regulatory point of view, the transition to a more predictive safety assessment of chemical and pharmaceutical substances requires the development of novel methods or models that reflect complex human physiology and biology in vitro.
In this respect, one of the fast-growing innovative technologies with promise is the organs-on-chip (OC) technology (Marx et al., 2016) . However, their value for regulatory safety assessment of chemical substances and pharmaceuticals is still unclear. Their role is in part dependent on the future development of regulatory safety assessment, which is widely recognized to be in need of a transition to accommodate the increased level of toxicological knowledge and animal welfare considerations (Piersma et al., 2018b) . Two main approaches can be distinguished in this transition to a more predictive and animal-free safety assessment: the "evolution" approach and the "revolution" approach (Scialli et al., 2018; Burgdorf et al., 2019) . The evolutionary approach represents the current practice of a more stepwise replacement of one animal test at a time by a set of non-animal methods that together predict the endpoint for which the animal test was designed. In the evolutionary approach, animal tests are often used as the gold standard. The revolutionary approach represents a more radical change in the safety assessment, starting with the identification of crucial mechanisms and biochemical events in clinical toxicity observations relevant for humans. These mechanisms and events should be at the basis of the development of a set of animalfree assays that together predict these toxicities. From this revolutionary perspective, it may occur that other toxicological endpoints are studied than the ones that are traditionally studied in animals. A revolution towards animal-free safety assessment is not expected to happen overnight, but gradually, parallel to the development of 3R methods that better fit into the ongoing evolutionary paradigm.
For the other part, the potential role of OCs in regulatory safety assessment is dependent on the possibilities they offer. To help regulators and innovators identify opportunities in the development of OCs and prioritize where resources are best used, it is crucial to identify the regulatory needs and compare the current availability, possibilities and limitations of OCs to these needs. McMullen et al. (2018) have introduced a stepwise approach for this, not focussing on OCs specifically but on all in vitro methods. While their study and ours share the same general approach, we have executed it differently, strengthening the very useful findings of McMullen et al. (2018) , but also adding different insights.
The current paper gives our view on the possibilities and limitations of OCs in the context of the transition to a more predictive, animal-free regulatory safety assessment. After a brief overview of the technical promises of OCs, we discuss how OCs can fit in both an 'evolutionary' as well as a 'revolutionary' transition. We add to the analysis of McMullen et al. (2018) , and discuss from a regulatory viewpoint the prioritization of organs and tissues needing an OC/in vitro assay, however, based on the analysis of a different database. In our analysis, based on the outcomes of a dedicated expert workshop, the regulatory needs are compared to the state of the art of OCs on several of these organs and tissues. Finally, we outline the challenges expected for implementation of this innovative technology for regulatory safety assessment purposes.
The promising features of organs-on-chip
OCs can be defined as three-dimensional (3D) tissue cultures (the mini "organ") applied in microfluidic systems (the "chip").
The microfluidic system allows flow of e.g. culture medium along or through the organ and may also allow stretching of the tissue to mimic breathing or peristaltic contraction of the intestine (Huh et al., 2010; Kim and Ingber, 2013) . This flow appears to cause cell barriers to polarize and differentiate, and to improve viability duration of cell cultures. As OCs are meant to mimic the smallest functional unit of an organ or tissue (Marx et al., 2016) , multiple cell types are typically included. OCs therefore represent the most complex form of in vitro cell cultures, with monolayers as its most simple form and 3D cultures as intermediate form. Also named micro physiological systems, these devices have shown tissue viability for 28 days or longer (e.g. (Baxter et al., 2015; Maschmeyer et al., 2015; Xiao et al., 2017) ). They therefore overcome two important challenges in studying complex, systemic toxicity endpoints and toxicokinetics: multiple interacting cell types and longer viability. In addition, many OCs have the possibility to be based on human cells, which may be more adequate to address human toxicity than animal models. OCs may also offer the opportunity to culture multiple tissues together and connect these by medium flow (e.g. (Maschmeyer et al., 2015; Oleaga et al., 2016) ), potentially allowing for toxicokinetics to be addressed simultaneously with toxicity. Some additional advantages of OCs in comparison to less complex in vitro models are given in Table 1 .
Tab. 1: Overview of advantages of OC devices compared to traditional in vitro assays Fluidic forces
Optimal transport of soluble cues can be applied in OCs and the exertion of shear stress through medium flow. It is established that cell behaviour is different in the presence of fluidic shear stress. The constant perfusion of fresh medium further prevents the decrease of pH, removes waste and provides a continuous source of nutrients.
Defined concentration gradients
Not only the fluid flow of the culture medium can be controlled in microfluidic devices, also complex concentration gradients are achievable. Repeated flow stream lamination can for example promote cell chemotaxis, i.e. the migration of cells in response to a stimulus.
Homogenous chemical distribution in medium
Only a small portion of the administered dose reaches the cell membrane. Colloidal behaviour, particle sedimentation and diffusion must be taken into consideration when correcting for the initial dose at the start of the experiment. With microfluidics, a homogenous suspension of substances in culture medium can be applied to the cell membrane under continuous perfusion, thereby creating a more physiologically relevant situation.
Micropatterning
Micropatterning allows for improved control over homo-and heterotypic cell-cell interactions and easier 3D culturing. These micropatterns can be used to control the geometry of adhesion and therefore the orientation of the cell division axis. It is also needed for the maintenance of stem cells or the exact positioning of a cell on a sensor.
Sensor integration
With the integration of biosensors in the device itself, a more reliable and quantitative monitoring of cell behaviour can be obtained (e.g. electrical activity, cytotoxicity measurements, optical sensors, cell-based biosensors, microscale patch clamp devices).
Mechanical strains
Cyclic mechanical strain can accentuate toxic and inflammatory effects and enhance the transport of particles over organ barriers.
Expanded cell viability
High, optimal control over environmental conditions for cell-based assays increases the cell viability and culture time. This has shown to lead to further differentiation of the cells towards improved physiological resemblance of the tissue. December 13, 2019 doi:10.14573/altex.1910111 3 3
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The role of OCs in an evolutionary transition of regulatory safety assessment
The idea behind an evolutionary transition to a more predictive, animal-free regulatory safety assessment is to gradually replace all regulatory required animal toxicity studies by (sets of) more predictive, animal-free methods. Currently, authorities have already accepted animal-free methods for some toxicity endpoints. For example, for assessing the irritation and corrosion, sensitization and genotoxicity potential of chemical substances, there are a number of OECD guidelines that make use of animal-free tests (Table 2) . These OECD TGs have undergone international validation and evaluation and are accepted by all OECD member countries. The safety evaluation of pharmaceuticals makes use of technical guidelines published by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). There is significant overlap between ICH and OECD test guidelines. It is evident from Table 2 that there is a lack of accepted animal-free methods for the more complex, systemic endpoints (acute toxicity, repeated dose toxicity, carcinogenicity, reproductive toxicity and neurotoxicity). In addition, only one OECD TG for an in vitro toxicokinetics assay exists: OECD TG 428 for dermal absorption. For absorption by inhalation and by ingestion, for liver metabolism and for kidney elimination, TGs for in vitro assays are lacking altogether.
To address these more complex toxicity endpoints, the human-based systems and longer viability options of OCs could potentially be of great value. Theoretically, from an evolutionary transition perspective, each animal study addressing complex toxicity endpoints could be replaced by a set of human-derived OCs of each organ evaluated in such a study. In combination with appropriate models for toxicokinetics, these OCs could then be used to derive safe limit values for humans.
Tab. 2: Generally required toxicity data in regulatory dossiers of chemical substances, the OECD test guidelines for animal methods producing such data, and available test guidelines or protocols for accepted animal-free methods.
Required toxicity data (by endpoint) OECD test guideline animal methods
OECD test guideline animal-free methods Acute toxicity (3 routes) 401, 402, 403, 436, 425, 423, 420, 433 Irritation/corrosion (eye and skin) 404, 405 460, 437, 438, 491, 492, 430, 431, 435, 439 Sensitisation 406, 429, 442A, 442B 442C, 442D, 442E Repeated dose toxicity 407, 408, 409, 410, 411, 412, 413, 452 Genotoxicity 488, 489, 483, 478, 475, 474, 473, 485, 484 471, 490, 487, 476 
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The role of OCs in a revolutionary transition of regulatory safety assessment
The revolutionary transition approach to a more predictive animal-free regulatory safety assessment does not necessarily require a one-by-one replacement of currently used animal studies. Instead, this approach can make use of the development of Adverse Outcome Pathways (AOPs). AOPs are at the basis of a mechanism-based toxicity approach by providing a structured representation of biological events leading to adverse effects, starting with a molecular initiating event (MIE) of a chemical that binds to a certain endogenous structure and leading to the final adverse outcome (AO) via several key events (KEs). An example of an AOP for Parkinsonian motor deficits is shown in Figure 1 . Ultimately, mechanisms of toxicity for diverse adverse health effects can be described by AOP networks, ideally in a quantitative manner (Pittman et al., 2018; Hassan et al., 2017) . The toxicity of chemical and pharmaceutical substances can then be predicted by testing their effects on the MIE and on KEs using designated animal-free methods. In the example above, the ultimate AO itself (in this case Parkinsonian motor deficits) is not detectable with an in vitro assay, but the steps leading to this AO can be measured in vitro (e.g. mitochondrial dysfunction or degeneration of dopaminergic neurons of the nigrostriatal pathway).
In this revolutionary approach, OCs may have great value in identifying the MIE and KEs of an AO in humans and in studying possible links between different AOPs. In addition, OCs may be better at detecting effects of substances on MIE and KEs, especially for those events that are difficult to determine using simpler methods. As was shown for the example of lung injury and disease, knowledge of the AOP underlying such AOs is necessary to know the components the model needs to include and the functions it needs to cover (McMullen et al., 2018) .
Integrating OCs with other safety assessment methods
It is important to note that OCs will seldom be the only method of choice, or even the first choice from multiple available methods when it comes to replacing current animal studies. Simpler and cheaper methods may be preferred, depending on their suitability to determine the AO at hand. In most cases, a set of test methods will be needed to replace one animal study or predict an AO, as is shown by the example of skin sensitisation (OECD, 2016a). Here, a set of relatively simple assays suffices to show that a substance induces the KEs involved. The use of multiple different methods aimed to address a certain type of toxicity can be combined in an Integrated Testing Strategy (ITS) or Integrated Approach to Testing and Assessment (IATA). In an IATA, information from multiple information sources, such as in chemico, in vitro, in vivo, or omics, is integrated and converted into a prediction model. Defined approaches (DAs) can also be part of IATAs. In DAs, data are generated by a defined selection of specific animalfree methods and subsequently evaluated by means of a fixed data interpretation procedure (OECD, 2016b) . For the case of skin sensitization, multiple different DAs can be designed for the same endpoint, as different assays and models can be selected and different combinations can be made. Some of the strategies for skin sensitisation provide information that can be used for hazard identification, e.g. distinguishing skin sensitizers from non-sensitizers, while other approaches provide information that allows potency sub-categorization as well (Ezendam et al., 2016) . The integration of an OC in an IATA may support more complex hazard assessment in cases where this is needed. The challenge that arises is how to deal with the large number of different approaches that would need to be assessed for suitability for regulatory purposes and how to perform such validations (Piersma et al., 2018a) , as will be discussed below. Recent grey literature on the subject includes two roadmaps: the US Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) strategic roadmap discusses the reasons for the paradigm shift on validation (ICCVAM, 2018) and the RIVM roadmap for animal-free innovations in regulatory safety testing describes the steps required to facilitate the transition to animal-free safety assessment including validation (RIVM, 2018) .
Prioritization of organs and tissues for developing OCs
For both the evolutionary as well as the revolutionary approach, replacing the animal studies by more predictive animal-free methods will likely take decades of research. In this challenge, it may help regulators and innovators to prioritize which organs are of most interest to develop into an OC. These would be the organs and tissues that are most often involved in manifestation of AOs upon chemical or pharmaceutical exposure in humans. Again, the development of an OC should only be prioritized if simpler or more suitable methods that cover the respective AO in the target tissue or organ are not feasible. Therefore, it would be valuable to analyse which KEs in what tissues are involved in AOs that are most relevant for humans. Ideally, one would analyse all AOPs to predict any type of adversity in humans, and subsequently identify the organs or tissues that are involved. Next, it would need to be assessed whether OCs are needed to assess effects on these KEs, or whether simpler methods exist. However, such a complete set of AOPs is not available yet, thus such an analysis is not yet possible. Instead, as a starting point, an indication of the organs most involved in determining adversity by chemical and pharmaceutical substances can be retrieved by studying data of animal toxicity studies. McMullen et al. (2018) have performed such an analysis on a collection of databases in the USA (the "Database Collection"), studying which systems most often led to a regulatory decision. They found that the liver was involved in most regulatory decisions, followed by the neurological, urinary and respiratory systems. While this provides a very useful insight, a limitation of this approach is that it is neglected which other organs may have shown an effect, even though it was not at the level of leading to a regulatory decision. We take a similar, but slightly different approach, based on an analysis of the RepDose database by Batke et al.
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Repeated dose toxicity
The current OECD guideline for repeated dose toxicity requires the evaluation of 21 tissues, but it is questionable whether analysis of all these tissues is needed. A study systematically analysing a database of 88 oral repeated dose toxicity studies on chemical substances showed that for 86% of the test substances, the lowest observed adverse effect level (LOAEL) can be derived by analysing only six organs/whole body symptoms (Batke et al., 2013) . A ranking of the organs/whole body symptoms based on how often these showed an effect at the dose identified as the LOAEL is given in Table 3 .
Tab. 3: Ranking of targets in 90-d oral rat studies, listed according to how often they showed an effect at the LOAEL Adapted from Batke et al. (2013) (Batke et al., 2013) . For the top ten of organs and tissues (bold), the availability of proof-ofconcept OCs is indicated. The availability of OC is concluded by experts at a dedicated workshop at RIVM in 2017 (see below). In the meantime, for stomach an OC model has been developed (Lee et al., 2018) . The top 10 of organs most involved in determining adverse effect levels in oral repeated dose toxicity studies is marked in bold. If simpler methods are not taken into account, these 10 organs offer a starting point to prioritize for OC development, with the following further considerations: − The forestomach is excluded from this top ten, as humans do not have this organ. The reason it is nevertheless analysed in animal studies is because it is the site of first contact for substances given by gavage, thus providing information on first-contact effects. − The dataset used by Batke et al. (2013) did not include inhalation and dermal studies, where most probably the lung and skin, respectively, would have ended up high in this ranking. Thus, these two organs are chosen to be added at the top of this table. It is noted that inhalation and dermal studies might have given a different order in the ranking of the other organs, had they been included.
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doi:10.14573/altex.1910111 6 − As the OECD TG for the 90-d oral study was revised in 1998 to derive more information from the study, it is possible that older studies in the RepDose database did not include as many parameters as newer studies, which would also affect the ranking. Furthermore, additional toxicity endpoints are being considered for inclusion in regulatory testing, such as endocrine disruption. This may also shift the priority for OC development to other or additional tissues. − These are data from rats, and the ranking might be different for humans. − Body weight and clinical symptoms cannot be analysed in in vitro methods such as OCs. Often, these symptoms will be the indirect result of effects in tissues and organs, in which case they are expected to be covered by analysing relevant biomarkers in these tissues and organs. In some cases, symptoms such as a decline in body weight or lethargy may be the first sign of distress, before any changes in currently used clinical biomarkers can be measured. The development of more sensitive parameters such as early KEs may overcome this limitation. The oral studies in the RepDose database showed that liver was most often involved in manifestation of AOs, followed by kidney and testes. By assumption, lung and skin would also rank high, in case inhalation and dermal studies would have been included. This may be in line with the findings of McMullen et al. (2018) , in whose database collection dermal studies are likely rare, possibly explaining that skin does not rank high (McMullen et al., 2018) . The difference in ranking between the testes and the neurological system is interesting and can as yet not be explained. The fact that only repeated dose toxicity studies were included in our study, while all types of toxicity studies were included in the analysis of McMullen et al. (2018), does not explain this difference. To our knowledge, a similar analysis as that of Batke et al. (2013) of organs and tissues most often involved in manifestation of AOs does not exist for other complex, systemic endpoints such as reproductive toxicity and immunotoxicity. The organs and tissues most involved in these endpoints may be different compared to those involved in repeated dose toxicity, as will be discussed below.
Reproductive toxicity
Reproductive toxicity involves effects on both fertility and developmental toxicity. Some effects on fertility can already be picked up by analysis of the gonads and uterus in a repeated dose testing setup, such as testes atrophy. However, for a more comprehensive assessment of effects on fertility, all organs involved in fertility would need to be covered by OCs and most importantly, they would need to be interconnected as a delicate hormone balance steer these processes. At the very least, an OC for the uterus, gonads (male and female) and fallopian tube would be necessary. One would expect that the organs involved in the reproductive endocrine system are necessary too, such as the hypothalamus and anterior pituitary. However, a full menstrual cycle with oocyte maturation in a microfluidic multi-organ setup without pituitary and hypothalamus has been reported (Xiao et al., 2017) . This development remains to be confirmed by further study. In any case, for fertility testing, single organs or tissues will not suffice; multi-organ setups with appropriate connections between the tissues are necessary.
Achieving an adequate OC for developmental toxicity testing may not be feasible at all, as this would imply the culture and exposure of human embryo's past the initial stages, which runs into ethical barriers. Other solutions are probably more appropriate, such as zebrafish embryo testing or computational modelling.
Carcinogenicity
Carcinogenicity can be detected partly by the genotoxicity assays for which animal-free methods are already available, although in the EU, in vitro testing alone is currently not accepted to be sufficient to address mutagenicity or genotoxic carcinogenicity, except for cosmetics. For the non-genotoxic carcinogens, no animal-free method is available yet. Nongenotoxic carcinogenicity may arise in any tissue, with some tissues having a higher exposure and thus a higher risk, or with some tissues being more sensitive for the carcinogenic effects of certain types of substances. For example, oestrogens can cause cancer mostly in tissues with high levels of a certain type of oestrogen receptor, such a breast tissue. Non-genotoxic carcinogenic mechanisms can be picked up through transcriptomic, biochemical and cell phenotypic analyses, which can be performed in the same in vitro tests as those used for repeated dose testing. As these changes occur much earlier than the emergence of a tumour, it is not to be expected that the test duration would need to be longer than that for repeated dose testing, thus merging these two endpoints. Whether additional tissues/organs would need to be included remains to be determined.
Neurotoxicity and immunotoxicity
Organs and tissues involved in neurotoxicity and immunotoxicity are included to some extent in current repeated dose testing, but this is mostly limited to histopathological evaluation. Due to increasing concerns about these endpoints, one could argue that more functional assays are needed. For neurotoxicity, obviously brain tissue and nerves are relevant, which have already been identified as important tissues involved in repeated dose toxicity. For immunotoxicity, spleen, thymus, lymph nodes and bone marrow are important tissues, some of which were also already identified as important in determining repeated dose toxicity. However, the immune system is much more complex and proper functioning is dependent on interaction between the different tissues. For this endpoint, determining the necessary tissues and their interrelations therefore deserves a more careful analysis.
Cardiotoxicity
While the heart is included in repeated dose testing of chemical substances, this is mostly limited to histopathological evaluation. For pharmaceuticals, cardiotoxicity testing is much more elaborate, including functional testing, as cardiotoxicity is one of the main reasons of product failure in relatively late stages of pharmaceutical drug development. However, the current testing strategy, which is in part based on animal testing, is subject of debate because of its poor predictive value (Pridgeon et al., 2018) . This in itself is a good reason to develop better models such as a heart-on-a-chip. For nonpharmaceuticals, the relevance of cardiotoxicity for humans is unknown due to a lack of regulatory testing requirements.
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Toxicokinetics endpoints
The major toxicokinetics endpoints for which animal-free methods are necessary are lung absorption, skin absorption, intestinal absorption, liver metabolism, protein binding, blood-tissue partitioning, and translocation over internal barriers, such as the blood-brain barrier, blood-testis barrier and placenta. As stated earlier, for skin absorption, an OECD TG already exists. Partitioning and protein binding (together dictating distribution) can be determined from the octanol-water partition coefficient (Kow) and a serum protein-binding assay that does not need tissue culture. Internal barrier passage, such as the blood-brain barrier, blood-testis barrier and placenta, are mostly relevant for the endpoints neurotoxicity, fertility and developmental toxicity, respectively. Some organs and tissues involved in kinetics such as lung, liver and kidney, have already been identified as a priority because of their important involvement in repeated dose toxicity. It should be noted that OCs to address repeated dose toxicity in these tissues and organs may not be suitable to address toxicokinetics. For example, for the evaluation of absorption, two compartments, one on each side of the tissue, are required, while for repeated dose toxicity, only one compartment would suffice. More refined toxicokinetics assessment can be performed when parameters such as bile excretion and sweat excretion are known, but these kinetic endpoints are of lower priority as they influence the total toxicokinetics to a lesser extent than the other parameters mentioned (Bessems et al., 2014) .
Workshop comparing regulatory toxicity testing needs to current state of the art of OCs
In June 2017, a workshop was held at RIVM to assess to what extent the current state-of-the-art of OC development met the needs of regulatory toxicity testing. The workshop was focused on ten tissues, organs and organ systems that are amongst those of highest importance for current regulatory toxicity testing (based on the above analysis): lung, skin, liver, kidney, heart, intestine, reproductive system, immune system, neuronal system and vascular system. Regulators and OC developers together discussed the needs, possibilities and limitations of developing OCs for this top-10.
State of the art
The workshop brought forward that OCs for lung, skin, liver, kidney, heart and intestine are already available, e.g. (Grosberg et al., 2011; Huh et al., 2010; Kim and Ingber, 2013; O'Neill et al., 2008; Vedula et al., 2017) , and even combined in multiorgan chips, e.g. (Maschmeyer et al., 2015; Oleaga et al., 2016; Wagner et al., 2013) (Table 3) . Together, these organs and tissues may already be able to cover aspects of kinetics, cardiotoxicity and repeated dose toxicity. The workshop participants agreed that they have reached a stage of development that now requires input from regulators on the precise needs in terms of features and functionalities per organ. For the other organ systems (reproductive system, immune system, neuronal system and vascular system), further research and development is necessary first. For the reproductive system, the OC state-of-the-art is a multiple organ system that has been reported to mimic a menstrual cycle (Xiao et al., 2017) . Although a major achievement, it still comprises only a small part of the whole reproductive process. The possibilities for mimicking the whole reproductive process are severely hampered by the difficulties in culturing the gonads, and the complex nature of the reproductive system, which necessitates multiple connected tissues and establishment of a delicate hormone balance. While technical challenges of culturing gonads and connecting multiple tissues may be solved with microfluidic systems, there are ethical restraints in culturing human stem cells and embryos, and thus limitations to what can be achieved with regard to mimicking the reproductive system using in vitro assays such as OCs.
Immunotoxicity is a collective name for many types of adverse immune effects, such as hypersensitivity, inflammation, immunosuppression and auto-immunity. Some relatively simple in vitro assays are already available that address certain types of immunotoxicity, while other types are much harder to address with simple in vitro assays, for example, because multiple organs and tissues are involved. The workshop participants recommended that first, a more thorough analysis is needed to identify the functionalities in immunotoxicity, after which it can be determined which organs and tissues are necessary to cover them.
In order to address neurotoxicity, a potential OC would need to be able to process information and transduce signals in ways similar to the human brain. However, the brain and associated neural system is of such a high complexity that it is understood relatively poorly, making the development of a system that can mimic it in the form of an organ on a chip extremely challenging. It was also questioned whether the level of an organ-on-a-chip would be necessary in this case, since a 3D culture format without microfluidics might suffice.
With regard to the vascular system, various research groups have already developed functional heart-on-a-chips for various purposes. Others have focused on developing blood vessels to be integrated into organ cultures. Nevertheless, systems that are able to mimic blood pressure changes, vascular dilation and contraction, plaque formation and angiogenesis are not yet available.
Priorities in further research
At the RIVM workshop, small discussion groups of regulators and developers held a further in-depth exchange on the features and functionalities that would be necessary (from the regulators' perspective) and are feasible (from the developers' perspective), for each of the ten organs or functional systems selected. These issues, presented per organ or functional system in Table 4 , can be considered a priority in further research.
Summary
The insights obtained in this workshop led to recommendations for regulators, on where their involvement is required when OCs are past the research and development stage and ready to move towards optimisation and possible implementation. The ALTEX preprint published December 13, 2019 doi:10.14573/altex.1910111 8 discussions showed that currently, regulators may play an important role in the optimisation of the lung, intestine, liver and kidney for toxicokinetics evaluation and repeated dose toxicity testing, as well as the optimisation of the heart for cardiotoxicity (= repeated dose toxicity) testing. Here, aspects such as the necessary level of complexity and the ease of application should be considered, after which further steps of standardisation, reproducibility testing, etc. can be undertaken towards acceptance and regulatory implementation. Furthermore, input of the workshop participants led to a list of priority issues per organ or functional system (Table 4) , to be tackled in further research and development of organs-on-chip. This outcome is somewhat different from that of McMullen et al. (2018) , who found that a key shortcoming in the current efforts is the ability to test volatile compounds and to predict pulmonary toxicity and therefore advise to focus on an in vitro system for the lung. While this is part of what we have found, too, our analysis was somewhat broader, e.g. also considering the needs for toxicokinetics, and we have differentiated which OCs are at a stage in which regulators should become involved for their optimisation and which OCs first need further (academic) development.
Tab. 4: Recommended priority list of research and development issues, per organ or functional system
The order of the organ or functional system is random, not following any prioritization.
Organ
Priority issues to be tackled − Determine immune function of the various organs, to put function-on-a-chip rather than organ-on-a-chip − Multiple organs on a chip mimicking immune response − Germinal centre on a chip − In vitro adaptive immune response Brain and other parts of the neuronal system − If OC needed, high volume system (analytical issue with detection limits) − For 3D brain, relation readouts with neurocognitive effects b Vascular system − Readouts for plaque formation and inflammation − Contraction and dilatation analysis − Control of pressure of vessel barrier and flow control through lumen − Angiogenesis a Already done for oocyte maturation (Xiao et al., 2017) ; b For a higher cognitive function, a more complex system is needed (layered structure).
Technical recommendations for regulatory valuable OCs
Apart from prioritizing the type of organs and tissues, a number of technical recommendations can be given to facilitate the development of OCs that can be successfully implemented in a regulatory context.
Predictive value
Naturally, an OC needs to be able to provide predictive information on the hazard or toxicokinetics of a chemical or pharmaceutical substance. The level of accuracy in this prediction depends in part on the type of regulatory safety assessment question at hand. To illustrate this, different questions and related predictive information requirements are shown for oral absorption of a chemical or pharmaceutical substance (Figure 2 ). This example shows how for certain regulatory questions, there is a need for an assay that can determine the precise rate and percentage of absorption of chemicals, while for others, a rough estimate will suffice. It is likely that OCs will have more value compared to simpler in vitro systems as the level of detail increases in the information required. 
Level of complexity
Closely related to the predictive value is the required level of complexity of an OC. One option (whether realistic or not) is to make an OC resemble human physiology as closely as possible, based on the hallmark of biology that structure and function are interrelated. A one-on-one resemblance to real tissue implies proper coverage of human physiology and KEs that are involved in AOPs. Achieving such close resemblance to real tissue would involve e.g. including multiple cell types and blood vessels in a 3D architecture on bio-based scaffolding with peristaltic movements in a flow-through system. However, this level of complexity is not always needed and even may have disadvantages such as higher costs, longer production times, higher failure rates and lower reproducibility between experiments and between labs. Microfluidics, for instance, may not be necessary for all purposes in regulatory safety assessment. Likewise, it may seem advantageous to measure as many parameters as possible in these systems, but the generation of large amounts of data may not be valuable or even become counterproductive if the data does not provide clear unambiguous answers. More data may sometimes only increase the uncertainty in the outcome of a test if the biological relevance of the data is not prioritized appropriately. Therefore, it is recommended to find the right balance between complexity (high biological accuracy, multi-organ-to human-on-a-chip) and ease, resulting in an OC fit-for-purpose to the regulatory needs. Again, this balance is dependent on the regulatory question at hand, as discussed above, thus probably multiple systems with differing levels of complexity will finally need to be available. For illustration purposes, some examples of different levels of complexity are discussed in Box 1-3 (absorption, liver clearance rate, liver fibrosis). In short, the advice is: keep the in vitro assays as simple as possible, but as complex as necessary.
Longevity
It was suggested that toxicity testing in OC models should align the exposure periods as dictated for animal testing (acute, subacute (28-d), subchronic (90-d), possibly even chronic) (Mastrangeli et al., 2019) . However, this may not be necessary in case OCs make use of readouts that allow for effects to be picked up at earlier time points, rather than mimicking the apical effects that are generally determined in animal studies. Here, the importance of developing AOPs is underlined, as evaluation of effects of substances on MIEs and KEs may facilitate the early detection of toxicity.
On the other hand, one should be aware that the mechanisms ensuring homeostasis are more comprehensive, diverse, and layered in a complete organism compared to an OC, even when the OC consists of multiple cell types that interact. The different events leading up to an AO may occur at different time points, i.e. to detect all KEs involved in an AOP in a single OC, long exposure durations may still be necessary. Therefore, the required longevity of a particular OC should be established on a case by case basis, may differ between different OCs and are likely not the same as for animal studies.
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doi:10.14573/altex.1910111 Box 1: Absorption For oral absorption, it has been found that the 2D monolayers of Caco-2 cells provide some qualitative information on the level of absorption of substances, but they are not suitable for precise determinations (Figure 2) . Addition of mucus-producing cells or flow of the medium has shown to highly impact the absorption of chemicals and nanoparticles (Shim et al., 2017) . Addition of a 3D collagen scaffold on which the Caco-2 cells are grown led to the production of mucus (Kim et al., 2014) and changed absorption of chemicals, both in static culture (Yu et al., 2012) and in cultures with flow (Shim et al., 2017) . Addition of flow of the medium plus a cyclic mechanical strain mimicking peristaltic movement was shown to induce the formation of villi-like structures in Caco-2 cells and to lead to differentiation into different cell types, including mucus-producing Goblet cells (Kim and Ingber, 2013) , which impact absorption. The expression of metabolic enzymes in the cells was also changed (Kim and Ingber, 2013; Shim et al., 2017) , which affected the apparent absorption of chemicals. For microparticles, the uptake may occur mainly through M-cells in the Peyers' patches in the intestine (Brun et al., 2014) , which would therefore need to be present to accurately determine the absorption of such particles. Finally, the presence of gut microbiota may also affect the (apparent) absorption. Thus, there are multiple factors that can be used to increase the complexity of the gut culture, potentially leading to a more accurate determination of absorption. It remains to be investigated which of these factors have the most impact and thus which minimal additions of complexity can lead to a sufficiently accurate and precise determination of absorption.
Box 2: Liver clearance rate
Liver clearance has been found to be reasonably well determined with suspensions of primary hepatocytes or HepaRG cells in case of fast to medium-fast metabolizing substances (Gouliarmou et al., 2018) . For slowly metabolizing substances, these cultures do not stay functional long enough (Lauschke et al., 2016) . There is therefore a need for a culture system that allows longer viability of hepatic cells, while maintaining the activity of their metabolizing enzymes. It has been shown that in a static culture, liver spheroids retained morphology, viability, and hepatocyte-specific functions for culture periods of at least 5 weeks (Bell et al., 2016) . It now remains to be verified whether the clearance of slowly metabolizing substances can be predicted sufficiently accurate with such a system, or whether additional complexity is necessary, e.g. by addition of other liver cell types or addition of medium flow.
Box 3: Liver fibrosis
For mimicking the process of liver fibrosis, as one of the main types of adverse effects in the liver, it has been shown that a static co-culture of three liver cell types is sufficient (Norona et al., 2016) . This bioprinted liver tissue, made with hepatocytes, stellate cells and endothelial cells, showed deposition of collagen after 14 days of treatment with fibrogenic agents. The flow of an OC therefore does not seem to be necessary. However, a simple culture of hepatocytes alone is not complex enough to obtain fibrosis.
Implementation challenges
Apart from the technical challenges and recommendations discussed above, several challenges exist in implementing these complex systems in regulatory toxicity testing, with regard to their standardization, validation, cost and other issues.
Standardization
After optimization of an OC to make it fit-for-purpose, as described above, it needs to be standardized. Standardization of an OC device involves the process of achieving uniform cells or tissue types that are compatible with chips and preferably can form compatible modules for interconnection into a multi-organ system. Moreover, standardization involves describing the preparation and use of an OC in such detail in an SOP that the results of the readouts are robust and reproducible. For complex systems as an OC, a rigorous and strict standardization of the methods will be necessary to achieve sufficient reproducibility. Helpful guidance documents for this are the OECD Guidance Documents 211 (OECD, 2014) and Good In Vitro Method Practices (OECD, 2018), on how to describe an in vitro assay and on what aspects and possible artefacts to consider when developing an in vitro method, respectively.
Validation
Some form of validation process will be needed for new test methods such as OCs before they can be implemented into a regulatory safety assessment context. Generally, this validation involves a long process of standardization and harmonization of the method, eventually leading to inclusion into technical guidelines such as those from the OECD or ICH, which paves the way for integration into legal frameworks by way of the Mutual Acceptance of Data (MAD) principle. For example, acceptance within the OECD test guidelines program requires an assessment of the relevance and reliability of a method, which is described in OECD Guidance Document (GD) 34. One aspect in this classical validation approach is comparison of the results of the new method with those of the "old" method, the golden standard, based on a variety of chemicals. This poses the question of how this validation process can be achieved for new technologies such as complex OCs and other methods and approaches aimed to replace animal studies. Most of these methods only cover part of a toxicity endpoint, so the results of the new method will not fully match those of the old method.
For this reason, the current validation process is now under debate. It is proposed that, in case of IATAs, quality criteria of reproducibility and transferability and description of chemical applicability domain remain essential at the level of individual assays (Piersma et al., 2018a) . However, validation in terms of predictive value of individual assays, based on a variety of chemicals, is no longer opportune. Rather, one could validate that the approach (e.g. IATA) offers sufficient coverage of the biological domain, i.e. by ensuring that all pathways that are relevant to e.g. liver toxicity are included in the new approach with proven functioning, using a set of assays. A challenge is that there may be multiple IATAs for the same toxicity endpoint, which would necessitate multiple validations. Clearly, this issue still needs further deliberation.
On another note, a more practical barrier for validation of OCs seems to be that in many cases, the ownership of the complete OC system lies with many different parties. Different companies develop and market the different components of ALTEX preprint published December 13, 2019 doi:10.14573/altex.1910111 11 an OC system: the microfluidic chip, the cells/tissue, and any scaffold (including gels) at minimum, and sometimes more specialized components e.g. for sensing. None is thus willing to invest alone in the validation of the complete OC, as the risk would then fall to one company, while others profit just as well. Multi-partner projects with a consortium of companies, each required to invest in part of the OC, could be a solution to breach this deadlock, perhaps under direction and with subsidy of the European Commission, in order to support the European business in this field. Involvement of regulators would help steer the validation towards regulatory acceptance, although it must be safeguarded that regulators do not give advantage to individual companies (see below).
Cost
Discussing the specific cost of OCs is difficult at this stage of development, but some general aspects may already be considered. The cost of OCs themselves will in part depend on whether they are purchased as plates/chips (requiring much in-house labour to add cells or tissues), or as ready-to-use models. Compared to more conventional, simple in vitro assays, OCs sometimes require expensive media and possibly expensive scaffolds for their culture. They may also require longer times to prepare, and often make use of longer test durations than other in vitro assays. Equipment for readouts is generally similar to that needed for other in vitro assays, thus not leading to much additional costs. However, overall, the use of OCs will probably lead to higher cost than those incurred for more conventional, simple in vitro assays.
On the other hand, the overall cost of OC may be lower when compared to animal tests, as the breeding and housing costs of animals may be higher and experimental durations may be longer. The cost of analysing the different parameters in multiple tissues is not expected to be very different between OC systems and the current animal tests. However, the comparison of costs between OCs and animal testing strongly depends on the set of OCs needed to replace animal testing.
Intellectual property
The competitiveness of many OC start-ups relies largely on the intellectual property (IP) licensed or owned. Since most OC devices can be easily reverse engineered, these are often not useful to protect by IP. Rather, tissue compositions, culture media compositions, hardware (such as sensors), and software can be protected by IP (Zhang and Radisic, 2017) . Since patent applications are not disclosed for a long period, it is difficult to get updates on current developments of a company.
Switching from PDMS prototyping (as PDMS is not a suitable material because it absorbs many chemicals) and smallseries to large-scale production in other materials requires redesign steps that will be very expensive for the relatively small companies involved. OC companies therefore need external partners and high financial investments to go through the prototyping phase and to scale up the production. Private investors seem have gained confidence in OC technology; in Europe, at least two companies succeeded to raise investor funds: Mimetas ($ 27.65M) and TissUse ($ 4.6M).
A different issue related to IP is the fact that the OECD is reluctant to accept guidelines that include models that are covered by IP, because they do not want to give any industry a monopoly position.
Availability of cells
Most OCs currently available use human cells because they are expected to better predict the human physiology compared to animal cells. If eventually OCs are implemented in a regulatory safety assessment context, this will significantly increase the demand for human cells. Furthermore, the use of primary cells is preferred because immortalized cell lines may deviate from the primary cells they originate from to such an extent that they lose their predictive potential. Researchers are now putting a lot of effort into obtaining human cell cultures from human stem cells, as these can provide an unlimited supply of "natural" human cells. However, pure, fully matured, differentiated cells from stem cells have not yet been obtained in vitro for all cell types. Often these cultures also contain immature cells which may not react in the same way as mature cells. This problem may be solved within a decade, as judged by the speed of developments in this field.
In the meantime, it is worthwhile to verify whether sufficient primary human cells may be available to enable replacement of animal testing. Enquiries among Dutch researchers learned that there are several biobanks, which can provide frozen human tissues but hardly any fresh tissues (Fentener van Vlissingen et al., 2017) . Furthermore, there is an abundant potential supply of vital, non-frozen human tissue available at the academic and peripheral hospitals of tissues such as skin, fat, blood (plasma) and uteri. Fresh colon, liver and lung tissue, originating e.g. from tumour resections, are less available.
Barriers in the ability to use fresh human tissue were mostly stated to lie in organisational and logistic problems. For example, in the Netherlands, there is no national standardised procedure to inform patients and obtain informed consent for further use of their tissue in research. In addition, hardly any (inter-)national or regional supply chains have been established. The European Network of Research Tissue Banks (ENRTB) is a first step in this direction, but further steps are necessary. The system that enables the availability of fresh viable human tissue to researchers currently works via personal connections and interests of doctors, pathologists and scientists, and is governed by Standard Operating Procedures (SOPs) specifically designed for each academic hospital.
In summary, for many primary human cells, their availability for OCs is more an issue of organizing a coordinated supply chain and resolving informed consent issues rather than the actual quantity of cells available. For other tissues, such as colon, liver, and lung, availability may be more of an issue. In these cases, enabling the consent to use donated transplantation organs for toxicity testing when they are eventually not used for transplantation, may be a potential solution. An effort from the governmental side to work on this consent, with consideration of the ethical issues, is advised.
Ethical issues with the use of OCs Currently, the use and sacrifice of animals for toxicity testing of chemical substances and pharmaceuticals is common practice, and is even required by many legislative frameworks. It is, however, by no means ethically neutral. Similar to the development of organoids, OCs hold the promise of a future without animal testing or at least contribute to the replacement, reduction and refinement of animal experiments for regulatory toxicity testing (Bredenoord et al., 2017) . Therefore, from the ALTEX preprint published December 13, 2019 doi:10.14573/altex.1910111 12 viewpoint of animal welfare, one may consider the use of OCs for toxicity testing more ethical than the use of animals. On the other hand, OCs may be associated with a different set of ethical issues. Firstly, there is an ongoing debate on whether it is justified to create and use human embryonic tissue for research (Bredenoord et al., 2017) , which is also relevant for OCs in case they make use of human embryonic stem cells. Positions in this debate vary from a human embryo deserving protection starting from fertilization, to the position of allowing the use of embryos for research under the condition that the providers of the gametes have given consent. Most countries allow embryo research under strict conditions, but do not allow deliberate creation of human embryos solely for research purposes. Instead, they restrict the use of embryos to those that are left over from in vitro fertilization procedures.
Secondly, when multi-organ-on-a-chip devices are further developed, they may come to a point where they mimic a human to such an extent, that the question may arise whether these systems should be seen as a human life form just as embryos from a certain developmental stage. In such a case, testing on these systems may be considered even more unethical than testing on animals. Lastly, the use of human (stem) cells, whether derived from embryos or adults, may raise issues of ownership and use and the need for informed consent by the donor of the cells. As discussed above, this could have an effect on the availability of cells.
Conclusions and outlook
OCs may play a role in future regulatory safety assessment of chemical and pharmaceutical substances, especially in the assessment of complex, systemic toxicity. OCs offer possibilities such as longer exposure durations and inclusion of multiple cell types, which might finally improve the prediction of complex, systemic AOs for which no non-animal approach currently exists. In addition, OCs may be valuable in studying the toxicokinetics of a chemical or pharmaceutical substance, e.g. by mimicking biological barriers and systems of metabolism. Clearly, there is still a lot of development work needed before OCs can be used for toxicological safety assessment. We recommend the development of OCs to go hand-in-hand with the development of AOPs, and combining them with other safety information into testing strategies such as IATAs.
From a preliminary example analysis of a repeated dose toxicity database, ten organs of priority for OC development for regulatory use have been identified. For a number of these organs (lung, skin, liver, kidney, heart and intestine), OCs are already at rather advanced stages of development, such that involvement of regulators becomes of value in the optimisation towards fitness-for-purpose of these methods. Regulatory risk assessors need to provide input on how the information generated from these systems can be integrated into a safety assessment, e.g. how the data can be used to derive a safe exposure limit or a classification and labelling category.
For organs such as spleen and testis, OCs are much more premature, if existing at all. Therefore, work on these organs will be mostly in the academic arena for the coming time. A major challenge is that for various toxicity endpoints, OCs of multiple organs need to be connected in some way to allow for interaction via metabolites, hormones, neurotransmitters, cytokines and other molecules regulating biological processes between organs.
A number of technical recommendations may be given: OCs (or in fact any in vitro method) should not become overly complex but fit-for-purpose, for which it must become clear what the regulatory purpose is exactly, and the duration of OC studies may probably be shorter than the current complex systemic animal studies. The implementation of OCs will face several challenges which need to be addressed: the current validation process does not seem opportune for OCs; there is a need for capital investment to reach final implementation, while each company only delivers part of an OC and therefore does not like to invest; there are some ethical issues; and the availability of human cells may become limiting.
In conclusion, while there is still much to be done, we feel that the development of OCs towards becoming part of regulatory safety assessment can benefit significantly from regular interactions between all stakeholders involved (see also Bos et al., submitted) . In this respect, workshops attended by developers, toxicologists and regulators, where information is exchanged on how OCs can be used for regulatory purposes, have proven to be a useful format for such interaction.
